AI-based drug discovery company Recursion raises $121M at a $646M valuation; VCs invested about $1B in AI drug discovery startups in 2018, up from $237M in 2016 (Robert Langreth/Bloomberg)

Robert Langreth / Bloomberg:
AI-based drug discovery company Recursion raises $121M at a $646M valuation; VCs invested about $1B in AI drug discovery startups in 2018, up from $237M in 2016  —  Alphabet´s DeepMind cracked a problem that long vexed biologists, heating up a technological arms race in health care

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok